<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK5188" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK5188/" /><meta name="ncbi_pagename" content="Chediak-Higashi Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Chediak-Higashi Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Chediak-Higashi Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/07/05" /><meta name="citation_author" content="Camilo Toro" /><meta name="citation_author" content="Elena-Raluca Nicoli" /><meta name="citation_author" content="May Christine Malicdan" /><meta name="citation_author" content="David R Adams" /><meta name="citation_author" content="Wendy J Introne" /><meta name="citation_pmid" content="20301751" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK5188/" /><meta name="citation_keywords" content="Lysosomal-trafficking regulator" /><meta name="citation_keywords" content="LYST" /><meta name="citation_keywords" content="Chediak-Higashi Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Chediak-Higashi Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Camilo Toro" /><meta name="DC.Contributor" content="Elena-Raluca Nicoli" /><meta name="DC.Contributor" content="May Christine Malicdan" /><meta name="DC.Contributor" content="David R Adams" /><meta name="DC.Contributor" content="Wendy J Introne" /><meta name="DC.Date" content="2018/07/05" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK5188/" /><meta name="description" content="Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism, immunodeficiency, and a mild bleeding tendency. Approximately 85% of affected individuals develop the accelerated phase, or hemophagocytic lymphohistiocytosis, a life-threatening, hyperinflammatory condition. All affected individuals including adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) develop neurologic findings during early adulthood." /><meta name="og:title" content="Chediak-Higashi Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism, immunodeficiency, and a mild bleeding tendency. Approximately 85% of affected individuals develop the accelerated phase, or hemophagocytic lymphohistiocytosis, a life-threatening, hyperinflammatory condition. All affected individuals including adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) develop neurologic findings during early adulthood." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK5188/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/chediak-higashi/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK5188/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8A5B77DFC93991000000000053002E.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK5188_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK5188_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cmtx5/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cherubism/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK5188_"><span class="title" itemprop="name">Chediak-Higashi Syndrome</span></h1><p class="contrib-group"><span itemprop="author">Camilo Toro</span>, MD, <span itemprop="author">Elena-Raluca Nicoli</span>, PharmR, PhD, <span itemprop="author">May Christine Malicdan</span>, MD, PhD, <span itemprop="author">David R Adams</span>, MD, PhD, and <span itemprop="author">Wendy J Introne</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK5188_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK5188_ai__"><div class="contrib half_rhythm"><span itemprop="author">Camilo Toro</span>, MD<div class="affiliation small">Staff Clinician, National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@corot" class="oemail">vog.hin.liam@corot</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Elena-Raluca Nicoli</span>, PharmR, PhD<div class="affiliation small">Visiting Fellow, National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@ilocin.acular" class="oemail">vog.hin@ilocin.acular</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">May Christine Malicdan</span>, MD, PhD<div class="affiliation small">Staff Scientist, National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@mnadcilam" class="oemail">vog.hin.liam@mnadcilam</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">David R Adams</span>, MD, PhD<div class="affiliation small">Staff Clinician, National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin@smada.divad" class="oemail">vog.hin@smada.divad</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Wendy J Introne</span>, MD<div class="affiliation small">Staff Clinician, National Human Genome Research Institute<br />National Institutes of Health<br />Bethesda, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.liam@enortniw" class="oemail">vog.hin.liam@enortniw</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 3, 2009</span>; Last Update: <span itemprop="dateModified">July 5, 2018</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="chediak-higashi.Summary" itemprop="description"><h2 id="_chediak-higashi_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Chediak-Higashi syndrome (CHS) is characterized by partial oculocutaneous albinism, immunodeficiency, and a mild bleeding tendency. Approximately 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop the accelerated phase, or hemophagocytic lymphohistiocytosis, a life-threatening, hyperinflammatory condition. All affected individuals including adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) develop neurologic findings during early adulthood.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of CHS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with giant inclusions within leukocytes on peripheral blood smear and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LYST</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Initial chemoimmunotherapy followed by transition to continuation therapy for the accelerated phase; allogenic HSCT as soon as possible to cure hematologic and immunologic defects; L-dopa may be considered for those with parkinsonism; home modifications and intensive rehabilitation for those with ataxia and other neurologic complications; corrective lenses to improve visual acuity; sunglasses to protect sensitive eyes from UV light; sunscreen to prevent sun damage and skin cancer.</p><p><i>Prevention of secondary complications:</i> Prompt aggressive use of antibiotics and antiviral agents for bacterial and viral illnesses; routine inactivated immunizations; intravenous DDAVP prior to invasive procedures to help control bleeding. Platelet transfusions as needed for serious bleeding.</p><p><i>Surveillance:</i> Routine monitoring for chimerism, as 20%-30% donor chimerism is likely enough to protect against reactivation. Yearly ophthalmologic, neurologic, and dermatologic examinations. For atypical or adolescent- or adult-onset CHS: annual abdominal ultrasound examination for hepatosplenomegaly; complete blood count for cytopenias; measurement of serum ferritin concentration and soluble interleukin-2 receptor; and monitoring for liver dysfunction.</p><p><i>Agents/circumstances to avoid:</i> Nonsteroidal anti-inflammatory drugs, which can exacerbate the bleeding tendency; live vaccines.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>CHS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. When both parents are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a>, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Prenatal diagnosis of CHS is possible if the pathogenic variants have been identified in the family.</p></div></div><div id="chediak-higashi.Diagnosis"><h2 id="_chediak-higashi_Diagnosis_">Diagnosis</h2><div id="chediak-higashi.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Diagnosis of Chediak-Higashi syndrome (CHS) <b>should be suspected</b> in individuals with any of the following clinical features and supportive laboratory findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Partial oculocutaneous albinism (OCA); a complete ophthalmologic examination may be necessary to identify the diagnostic finding of reduced iris pigment manifest as iris transillumination or reduced retinal pigmentation.</div></li><li class="half_rhythm"><div>A significant history of infections, particularly bacterial infections of the skin and respiratory tract</div></li><li class="half_rhythm"><div>Mild bleeding tendency</div></li><li class="half_rhythm"><div>Childhood- to early adult-onset neurologic manifestations, including:</div><ul><li class="half_rhythm"><div>Cognitive impairment</div></li><li class="half_rhythm"><div>Peripheral neuropathy</div></li><li class="half_rhythm"><div>Ataxia</div></li><li class="half_rhythm"><div>Parkinsonism</div></li></ul></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div>Giant inclusions in polymorphonuclear neutrophils (PMNs) and (to a lesser extent) in lymphocytes</div><ul><li class="half_rhythm"><div>This is the most reliable diagnostic criterion for CHS but may be overlooked in a routinely evaluated CBC unless a peripheral smear is reviewed.</div></li><li class="half_rhythm"><div>The giant granules are seen using routine staining techniques; however, in some atypical cases, the presence of these giant granules can be somewhat subtle.</div></li><li class="half_rhythm"><div>A hematologist, or a clinician experienced in reviewing blood smears for the presence of these giant granules, should review the slide.</div></li><li class="half_rhythm"><div>Peroxidase-positive giant inclusions can be seen in leukocytes, megakaryocytes, and other bone marrow precursors (<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">Figure 1c</a>-<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">1e</a>).</div></li></ul></li><li class="half_rhythm"><div>Normal or reduced number of natural killer cells with abnormal (reduced) function</div></li><li class="half_rhythm"><div>Neutropenia and impaired neutrophil function (particularly chemotaxis and intracellular bactericidal activity). Note: Immunoglobulins, complement, antibody production, and delayed hypersensitivity are all normal.</div></li><li class="half_rhythm"><div>Absent or reduced number and irregular morphology of platelet-dense bodies (required for the secondary wave of platelet aggregation) on whole-mount electron microscopy (<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">Figure 1a</a>, <a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">1b</a>)</div></li><li class="half_rhythm"><div>Pigment clumping on polarized light microscopy hair analysis (<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">Figure 1f</a>, <a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">1g</a>).</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="figchediakhigashiF1" co-legend-rid="figlgndchediakhigashiF1"><a href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" title="Figure 1" class="img_link icnblk_img figpopup" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1"><img class="small-thumb" src="/books/NBK5188/bin/chediak-higashi-Image001.gif" src-large="/books/NBK5188/bin/chediak-higashi-Image001.jpg" alt="Figure 1. a." /></a><div class="icnblk_cntnt" id="figlgndchediakhigashiF1"><h4 id="chediak-higashi.F1"><a href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-ob="figobchediakhigashiF1">Figure 1</a></h4><p class="float-caption no_bottom_margin">a. Whole-mount electron microscopy of control platelets shows several dense bodies per platelet (arrows). b. Some CHS platelets have no dense bodies (asterisk) and others have irregular electron-dense granules (arrows).</p></div></div><p>Note: Because the finding of WBC giant inclusions is the most reliable clinical diagnostic criterion, the combination of any other of the above features should prompt review of a peripheral blood smear evaluating for giant inclusions.</p></div><div id="chediak-higashi.Establishing_the_Diagnos"><h3>Establishing the Diagnosis</h3><p>The diagnosis of Chediak-Higashi syndrome <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with giant inclusions within leukocytes on peripheral blood smear and/or by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>LYST</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK5188/table/chediak-higashi.T.molecular_genetic_test/?report=objectonly" target="object" rid-figpopup="figchediakhigashiTmoleculargenetictest" rid-ob="figobchediakhigashiTmoleculargenetictest">Table 1</a>).</p><p>When the phenotypic and laboratory findings suggest the diagnosis of Chediak-Higashi syndrome, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>LYST</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected. Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found, perform gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>LYST</i> and other genes of interest (see <a href="#chediak-higashi.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="chediak-higashi.T.molecular_genetic_test" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.molecular_genetic_test/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.molecular_genetic_test_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>LYST</i></td><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~90%</td></tr><tr><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6</sup></td><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">NA</td><td headers="hd_h_chediak-higashi.T.molecular_genetic_test_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.1.1"><p class="no_margin">See <a href="/books/NBK5188/#chediak-higashi.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.1.2"><p class="no_margin">See <a href="#chediak-higashi.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="chediak-higashi.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="chediak-higashi.TF.1.5"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>6. </dt><dd><div id="chediak-higashi.TF.1.6"><p class="no_margin">Pathogenic variants in other genes are not known to result in CHS. Although it had been previously reported that a lower <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detection rate suggested the possibility of <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> heterogeneity [<a class="bk_pop" href="#chediak-higashi.REF.karim.2002.16">Karim et al 2002</a>], the detection method in use was single-strand conformational <a class="def" href="/books/n/gene/glossary/def-item/polymorphism/">polymorphism</a> (SSCP) analysis, which has a lower rate of detection than sequencing of the entire <a class="def" href="/books/n/gene/glossary/def-item/open-reading-frame/">open reading frame</a> [<a class="bk_pop" href="#chediak-higashi.REF.zarzour.2005.125">Zarzour et al 2005</a>]. However, because the function of the lysosomal trafficking regulator protein encoded by <i>LYST</i> is largely unknown, it is possible that pathogenic variants in other genes whose products interact with LYST could also result in CHS.</p></div></dd></dl></div></div></div></div></div><div id="chediak-higashi.Clinical_Characteristics"><h2 id="_chediak-higashi_Clinical_Characteristics_">Clinical Characteristics</h2><div id="chediak-higashi.Clinical_Description"><h3>Clinical Description</h3><p>Chediak-Higashi syndrome (CHS) is characterized by oculocutaneous albinism (OCA), immunodeficiency, and a mild bleeding tendency. Approximately 85% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop the accelerated phase, or hemophagocytic lymphohistiocytosis (HLH), a life-threatening, hyperinflammatory condition. All affected individuals &#x02013; including adolescents and adults with atypical CHS and children with classic CHS who have successfully undergone allogenic hematopoietic stem cell transplantation (HSCT) &#x02013; develop neurologic findings.</p><p><b>Partial OCA.</b> Pigment dilution is highly variable, but can involve hair, skin, and eyes. In classic forms of CHS, the hair has a "silvery" or metallic appearance. Skin pigment dilution may not be appreciated unless compared to that of family members. Reduced iris pigmentation may also be subtle, particularly in individuals with darkly pigmented irides. Affected individuals may have decreased retinal pigmentation and nystagmus. Visual acuity varies from normal to moderate impairment. Quantitative data are not available and are difficult to obtain given the young age of individuals with the classic presentation.</p><p>OCA was once thought to be a diagnostic criterion for CHS; however, at least two individuals with atypical CHS had no evidence of OCA [<a class="bk_pop" href="#chediak-higashi.REF.introne.2017.e57">Introne et al 2017</a>].</p><p>Pigment clumping within the shaft of the hair is generally observed under the light microscope (<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">Figure 1g</a>) [<a class="bk_pop" href="#chediak-higashi.REF.smith.2005.1294">Smith et al 2005</a>].</p><p><b>Immunodeficiency.</b> Frequent infections usually begin in infancy and are often severe in the classic form of this condition. Bacterial infections are most common, with <i>Staphylococcus</i> and <i>Streptococcus</i> species predominating; viral and fungal infections can also occur [<a class="bk_pop" href="#chediak-higashi.REF.introne.1999.283">Introne et al 1999</a>]. Infections of the skin and upper respiratory tract are the most common. Case reports have identified periodontitis as an important manifestation of immunologic dysfunction [<a class="bk_pop" href="#chediak-higashi.REF.hart.2007.95">Hart &#x00026; Atkinson 2007</a>, <a class="bk_pop" href="#chediak-higashi.REF.khocht.2010.49">Khocht et al 2010</a>]. In some instances periodontitis can be the clinical finding leading to correct diagnosis [<a class="bk_pop" href="#chediak-higashi.REF.bailleulforestier.2008.1263">Bailleul-Forestier et al 2008</a>].</p><p>Individuals with atypical CHS may not have a history of unusual or severe infections.</p><p><b>Bleeding tendency.</b> Clinical manifestations are generally mild and include epistaxis, gum/mucosal bleeding, and easy bruising. The bleeding diathesis in CHS may also be subtle (i.e., generally not requiring medical intervention). Bleeding problems may not be listed as a health concern by <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> persons.</p><p><b>Accelerated phase.</b> The accelerated phase, occurring in up to 85% of individuals with CHS [<a class="bk_pop" href="#chediak-higashi.REF.blume.1972.247">Blume &#x00026; Wolff 1972</a>], can occur at any age. Clinical manifestations include fever, lymphadenopathy, hepatosplenomegaly, anemia, neutropenia, and sometimes thrombocytopenia. Originally thought to be a malignancy resembling lymphoma, the accelerated phase is now known to be HLH characterized by multiorgan inflammation. The accelerated phase and its complications are the most common cause of mortality in individuals with CHS [<a class="bk_pop" href="#chediak-higashi.REF.eapen.2007.411">Eapen et al 2007</a>].</p><p>Triggers of the accelerated phase remain unclear. Infection with Epstein-Barr virus is thought to hasten development of the accelerated phase, although this relationship has never been proven. Abnormal function of NK cells and cytolytic T cells is also believed to contribute to development of the accelerated phase [<a class="bk_pop" href="#chediak-higashi.REF.jessen.2011.4620">Jessen et al 2011</a>, <a class="bk_pop" href="#chediak-higashi.REF.gilkrzewska.2016.1165">Gil-Krzewska et al 2016</a>].</p><p><b>Neurologic disease.</b> Despite successful hematologic and immunologic outcomes with allogenic HSCT, neurologic disease still manifests by early adulthood. Findings are the same as those described in untransplanted individuals with atypical or adolescent forms of the disease, but are highly variable and nonspecific [<a class="bk_pop" href="#chediak-higashi.REF.introne.2017.e57">Introne et al 2017</a>].</p><ul><li class="half_rhythm"><div>Progressive neurologic findings can include:</div><ul><li class="half_rhythm"><div>Slowly progressive intellectual disabilities</div></li><li class="half_rhythm"><div>Sensory or sensorimotor neuropathies and/or a diffuse motor neuronopathy [<a class="bk_pop" href="#chediak-higashi.REF.lehky.2017.359">Lehky et al 2017</a>]</div></li><li class="half_rhythm"><div>Balance abnormalities</div></li><li class="half_rhythm"><div>Tremor</div></li><li class="half_rhythm"><div>Parkinsonism [<a class="bk_pop" href="#chediak-higashi.REF.bhambhani.2013.127">Bhambhani et al 2013</a>, <a class="bk_pop" href="#chediak-higashi.REF.weisfeldadams.2013.46">Weisfeld-Adams et al 2013</a>]</div></li><li class="half_rhythm"><div>Spastic paraplegia [<a class="bk_pop" href="#chediak-higashi.REF.shimazaki.2014.1024">Shimazaki et al 2014</a>]</div></li></ul></li><li class="half_rhythm"><div>Neurodegeneration following successful bone marrow transplantation was first described by <a class="bk_pop" href="#chediak-higashi.REF.tardieu.2005.40">Tardieu et al [2005]</a> in 11 children who were transplanted at their center.</div><ul><li class="half_rhythm"><div>All 11 exhibited neurologic manifestations primarily consisting of low cognitive abilities, balance abnormalities and ataxia, tremor, absent deep-tendon reflexes, and motor and sensory neuropathies.</div></li><li class="half_rhythm"><div>The authors concluded that the neurologic changes were a result of long-term progression of the disease rather than neurotoxic effects of the transplant-conditioning regimen or the accelerated phase.</div></li></ul></li></ul><p><b>Atypical phenotypes.</b> An unknown fraction of individuals with CHS have atypical or milder phenotypes [<a class="bk_pop" href="#chediak-higashi.REF.karim.2002.16">Karim et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>], which are likely underrecognized. Some of these <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be diagnosed after the third decade of life [<a class="bk_pop" href="#chediak-higashi.REF.weisfeldadams.2013.46">Weisfeld-Adams et al 2013</a>]. Atypical phenotypes are characterized by the following:</p><ul><li class="half_rhythm"><div>OCA that is generally subtle or absent</div></li><li class="half_rhythm"><div>Insignificant infections or severe infections during childhood that become much less frequent later in life</div></li><li class="half_rhythm"><div>Reduced platelet-dense bodies with subtle bleeding manifestations</div></li><li class="half_rhythm"><div>In some cases, neurodegeneration (similar to that seen in the classic <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>) as the predominant manifestation, with only mild alterations in pigmentation, immune function, and bleeding</div></li><li class="half_rhythm"><div>Abnormal granules within leukocytes (present in all individuals with an atypical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>)</div></li></ul></div><div id="chediak-higashi.GenotypePhenotype_Correl"><h3>Genotype-Phenotype Correlations</h3><p>Clinical phenotypes of CHS have been correlated with molecular genotypes [<a class="bk_pop" href="#chediak-higashi.REF.karim.2002.16">Karim et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.zarzour.2005.125">Zarzour et al 2005</a>]:</p><ul><li class="half_rhythm"><div>In general, <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> variants are associated with severe, childhood-onset form and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants with milder adolescent- or adult-onset forms of the disorder [<a class="bk_pop" href="#chediak-higashi.REF.karim.2002.16">Karim et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.zarzour.2005.125">Zarzour et al 2005</a>, <a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>]. However, exceptions have been reported: individuals with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> missense variants who present with the severe, childhood-onset form and HLH [<a class="bk_pop" href="#chediak-higashi.REF.s_nchezguiu.2014.49">S&#x000e1;nchez-Guiu et al 2014</a>].</div></li><li class="half_rhythm"><div>It has been shown that the clinical severity of the disease also correlates with the cellular <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Detailed studies of fibroblasts and melanocytes from individuals with CHS with different clinical phenotypes illustrated the range of enlargement of intracellular granule abnormalities in different CHS cell types [<a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>].</div></li></ul></div><div id="chediak-higashi.Prevalence"><h3>Prevalence</h3><p>Fewer than 500 cases have been reported in the literature [<a class="bk_pop" href="#chediak-higashi.REF.kaplan.2008.22">Kaplan et al 2008</a>]. Exact prevalence is difficult to determine as some individuals are reported in the literature more than once. In addition, the phenotypic variability that has more recently been appreciated suggests that many mildly <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals may be unrecognized or unreported.</p></div></div><div id="chediak-higashi.Genetically_Related_Alle"><h2 id="_chediak-higashi_Genetically_Related_Alle_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with mutation of <i>LYST</i>.</p><p>Variability of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> has been appreciated and is influenced by the location and type of pathogenic variants. See <a href="#chediak-higashi.Clinical_Description">Clinical Description</a>, <b>Atypical phenotypes</b> for additional information.</p></div><div id="chediak-higashi.Differential_Diagnosis"><h2 id="_chediak-higashi_Differential_Diagnosis_">Differential Diagnosis</h2><p>The diagnosis of Chediak-Higashi syndrome (CHS) should be considered in individuals with pigment dilution defects of the hair, skin, or eyes; <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> or transient neutropenia; immunodeficiency; and otherwise unexplained neurologic abnormalities or neurodegeneration. Each of these findings may be variably represented in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; therefore, heightened suspicion is needed to pursue an accurate diagnosis.</p><p><b>Oculocutaneous albinism.</b> The seven types of oculocutaneous albinism (<a href="/books/n/gene/oca1/">OCA type 1</a>, <a href="/books/n/gene/oca2/">OCA type 2</a>, OCA type 3, <a href="/books/n/gene/oca4/">OCA type 4</a>, OCA type 5, OCA type 6, and OCA type 7) and <a href="/books/n/gene/x-oa/">OA</a> (ocular albinism) all feature visual impairment and varying degrees of iris/retinal depigmentation. Characteristic skin and hair findings vary from complete absence of pigment to reduced pigment, except in individuals with OA, in whom skin and hair pigment may be normal, and in OCA type 3, which is characterized by bright copper-red hair and lighter tan skin. Neither an infectious history resulting from neutropenia nor neurologic abnormalities accompany the OCA types. OCA is common enough (~1:18,000) that it may coexist with other conditions, including primary immunodeficiencies.</p><p><a href="/books/n/gene/hps/"><b>Hermansky Pudlak syndrome</b></a>
<b>(HPS).</b> Like CHS, HPS is an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder characterized by OCA and a bleeding diathesis secondary to absent platelet-dense bodies. Of the at least ten subtypes of HPS, HPS2 (caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>AP3B1</i>) most closely resembles CHS.</p><p>HPS2 has been reported in at least 30 individuals [<a class="bk_pop" href="#chediak-higashi.REF.jessen.2013.2943">Jessen et al 2013</a>; Huizing et al, unpublished] (see <a href="/books/n/gene/hps/">Hermansky-Pudlak Syndrome</a>). In addition to the albinism and bleeding diathesis, individuals with HPS2 also have <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> neutropenia, a recurrent pattern of severe bacterial infections, and pulmonary fibrosis. Patients with HPS2 are at risk for HLH, although the risk is less than for CHS and GS. The distinction between CHS and HPS2 depends on identifying giant intracellular granules within the neutrophils of those individuals with CHS.</p><p><b>Griscelli syndrome (GS)</b> (OMIM <a href="https://omim.org/phenotypicSeries/PS214450" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">PS214450</a>). Mild skin hypopigmentation and silvery gray hair are present, but platelet function is normal. Griscelli syndrome may be caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in:</p><ul><li class="half_rhythm"><div><i>MYO5A</i> (GSI), characterized by severe neurologic involvement [<a class="bk_pop" href="#chediak-higashi.REF.pastural.1997.289">Pastural et al 1997</a>];</div></li><li class="half_rhythm"><div><i>RAB27A</i> (GSII), leading to immunodeficiency and lymphohistiocytosis [<a class="bk_pop" href="#chediak-higashi.REF.m_nasch_.2000.173">M&#x000e9;nasch&#x000e9; et al 2000</a>]; and</div></li><li class="half_rhythm"><div><i>MLPH</i> (GSIII), with hypopigmentation as its only clinical characteristic [<a class="bk_pop" href="#chediak-higashi.REF.m_nasch_.2003.450">M&#x000e9;nasch&#x000e9; et al 2003</a>].</div></li></ul><p><b>Cross syndrome</b> (OMIM <a href="https://omim.org/entry/257800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">257800</a>). Cross syndrome is characterized by hypopigmentation, ocular defects, and severe developmental delay reflecting extensive central nervous system involvement. An infectious component is absent from this diagnosis.</p><p><b>Immunodeficiency due to defect in MAPBP-interacting protein</b> (OMIM <a href="https://omim.org/entry/610798" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">610798</a>) is a novel immunodeficiency syndrome identified in four members of a Mennonite <a class="def" href="/books/n/gene/glossary/def-item/pedigree/">pedigree</a> [<a class="bk_pop" href="#chediak-higashi.REF.bohn.2007.38">Bohn et al 2007</a>]. Clinical features include partial albinism, short stature, <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> neutropenia, and lymphoid deficiency. Neutrophils show altered azurophilic granule ultrastructure and less than normal microbicidal function of phagosomes, in contrast to the giant inclusions seen in neutrophils in CHS. Neurologic dysfunction was not described in members of this pedigree. Biallelic pathogenic variants in <i>LAMTOR2</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p><p><b>Familial hemophagocytic lymphohistiocytosis</b>
<b>(FHL)</b> is characterized by proliferation and infiltration of hyperactivated macrophages and T-lymphocytes manifesting as acute illness with prolonged fever, cytopenias, and hepatosplenomegaly. Onset is typically within the first few months of life and, on occasion, in utero, although later childhood or adult onset is more common than previously suspected. Neurologic abnormalities that may be present initially or may develop later include: increased intracranial pressure, irritability, neck stiffness, hypotonia, hypertonia, convulsions, cranial nerve palsies, ataxia, hemiplegia, quadriplegia, blindness, and coma. Rash and lymphadenopathy are less common. Other findings include liver dysfunction and bone marrow hemophagocytosis. The median survival of children with typical FHL, without treatment, is less than two months; progression of hemophagocytic lymphohistiocytosis and infection account for the majority of deaths in untreated individuals. Familial HL, inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner, is caused by <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> variants in <i>PRF1</i>, <i>STX11</i>, <i>STXBP2</i>, or <i>UNC13D</i>.</p><p><b>Vici syndrome</b> (OMIM <a href="https://omim.org/entry/242840" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">242840</a>). A small number of individuals with cutaneous hypopigmentation, combined immunodeficiency, agenesis of the corpus callosum, bilateral cataracts, and cleft lip and palate have been described. Cognitive impairment, seizures, and severe respiratory infections were observed [<a class="bk_pop" href="#chediak-higashi.REF.dionisi_vici.1988.1">Dionisi Vici et al 1988</a>, <a class="bk_pop" href="#chediak-higashi.REF.del_campo.1999.479">del Campo et al 1999</a>, <a class="bk_pop" href="#chediak-higashi.REF.chiyonobu.2002.61">Chiyonobu et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.miyata.2007.189">Miyata et al 2007</a>]. Biallelic pathogenic variants in <i>EPG5</i> are causative; inheritance is <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>.</p></div><div id="chediak-higashi.Management"><h2 id="_chediak-higashi_Management_">Management</h2><div id="chediak-higashi.Evaluations_Following_In"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with Chediak-Higashi syndrome (CHS), the evaluations detailed in <a class="figpopup" href="/books/NBK5188/table/chediak-higashi.T.recommended_evaluation/?report=objectonly" target="object" rid-figpopup="figchediakhigashiTrecommendedevaluation" rid-ob="figobchediakhigashiTrecommendedevaluation">Table 2</a> are recommended if they have not already been completed.</p><div id="chediak-higashi.T.recommended_evaluation" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Recommended Evaluations Following Initial Diagnosis in Individuals with Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.recommended_evaluation/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.recommended_evaluation_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Hematologic</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">History of unexplained, persistent, or recurrent fever</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">To assess for evidence of the accelerated phase&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Assessment for hepatosplenomegaly by physical examination &#x00026; ultrasound imaging</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Complete blood count&#x000a0;<sup>1</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Ferritin concentration&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Soluble interleukin-2 receptor level&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Consideration of bone marrow biopsy&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Immunologic</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Screening for history of frequent or unusual infections</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to immunologist &#x00026;/or hematologist as needed</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Gastrointestinal</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Serum triglyceride concentration</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">To assess for liver dysfunction&#x000a0;<sup>5</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Fibrinogen level</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Neurologic</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Complete neurologic evaluation</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consideration of lumbar puncture</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To assess for evidence of hemophagocytosis in cerebrospinal fluid</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Ocular</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmology evaluation</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For signs of reduced pigment &#x00026; refractive errors</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Other</b></td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consultation w/clinical geneticist &#x00026;/or genetic counselor</td><td headers="hd_h_chediak-higashi.T.recommended_evaluation_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.2.1"><p class="no_margin">For evidence of cytopenia involving at least two cell lines</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.2.2"><p class="no_margin">Elevated serum ferritin and soluble interleukin-2 receptor level are associated with the accelerated phase.</p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.2.3"><p class="no_margin">To assess for hemophagocytosis</p></div></dd><dt>4. </dt><dd><div id="chediak-higashi.TF.2.4"><p class="no_margin"><a class="bk_pop" href="#chediak-higashi.REF.filipovich.2006.410">Filipovich [2006]</a></p></div></dd><dt>5. </dt><dd><div id="chediak-higashi.TF.2.5"><p class="no_margin">Hypertriglyceridemia and hypofibrinogenemia are suggestive of liver dysfunction, which can be associated with the accelerated phase.</p></div></dd></dl></div></div></div></div><div id="chediak-higashi.Treatment_of_Manifestati"><h3>Treatment of Manifestations</h3><div id="chediak-higashi.T.treatment_of_manifesta" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Treatment of Manifestations in Individuals with Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.treatment_of_manifesta/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.treatment_of_manifesta_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment</th><th id="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Hematologic and immunologic defects</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Guidelines for treatment of the accelerated phase are the same as for <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> hemophagocytic lymphohistiocytosis (HLH).&#x000a0;<sup>1,&#x000a0;2,&#x000a0;3,&#x000a0;4</sup></td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Combination therapy consists of etoposide &#x00026; dexamethasone, w/continuation phase adding cyclosporine A.</div></li><li class="half_rhythm"><div>Select individuals may also receive intrathecal methotrexate.</div></li></ul>
</td></tr><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Hematopoietic stem cell transplantation (HSCT)&#x000a0;<sup>5,&#x000a0;6,&#x000a0;7,&#x000a0;8</sup></td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>HSCT is often initiated as soon as the diagnosis is confirmed.</div></li><li class="half_rhythm"><div>The most favorable outcome is achieved when HSCT is performed prior to development of the accelerated phase.</div></li><li class="half_rhythm"><div>If signs of the accelerated phase are present, hemophagocytosis must be brought into clinical remission before HSCT can be performed.&#x000a0;<sup>4</sup></div></li></ul>
</td></tr><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Parkinsonism</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Trial of L-dopa therapy&#x000a0;<sup>9</sup></td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ataxia</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Intensive rehabilitation (or coordinative physiotherapy)</div></li><li class="half_rhythm"><div>Canes/walkers to prevent falls</div></li><li class="half_rhythm"><div>Home modifications to accommodate motorized chairs, as needed</div></li><li class="half_rhythm"><div>Weighted eating utensils &#x00026; dressing hooks</div></li><li class="half_rhythm"><div>Weight control, as obesity can exacerbate difficulties w/ambulation &#x00026; mobility</div></li></ul>
</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Treatment is best provided by a multidisciplinary team comprising a neurologist, physiatrist, &#x00026; physical &#x00026; occupational therapists.</td></tr><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Refractive errors &#x00026;/or light <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a></td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Corrective lenses for refractive errors</div></li><li class="half_rhythm"><div>Sunglasses to protect sensitive eyes from UV light</div></li><li class="half_rhythm"><div>Low vision rehabilitation &#x00026; adaptive therapy</div></li></ul>
</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Referral to ophthalmologist</td></tr><tr><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin hypopigmentation</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sunscreen</td><td headers="hd_h_chediak-higashi.T.treatment_of_manifesta_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">To prevent sun damage &#x00026; skin cancer</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.3.1"><p class="no_margin">Better HLH control at the time of HSCT leads to better long-term outcome.</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.3.2"><p class="no_margin">Recent evaluation of HLH-2004 protocol did not find statistical evidence for superiority over the HLH-94 regimen; therefore, HLH-94 remains the standard of care [<a class="bk_pop" href="#chediak-higashi.REF.bergsten.2017.2728">Bergsten et al 2017</a>].</p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.3.3"><p class="no_margin">The remission induction rate may be as high as 71% when considering all heritable causes of HLH [<a class="bk_pop" href="#chediak-higashi.REF.filipovich.2015.895">Filipovich &#x00026; Chandrakasan 2015</a>].</p></div></dd><dt>4. </dt><dd><div id="chediak-higashi.TF.3.4"><p class="no_margin">This treatment is also effective at inducing remission in CHS so that HSCT can be performed [<a class="bk_pop" href="#chediak-higashi.REF.trottestam.2009.268">Trottestam et al 2009</a>].</p></div></dd><dt>5. </dt><dd><div id="chediak-higashi.TF.3.5"><p class="no_margin">This is the only treatment that cures the hematologic and immunologic deficits.</p></div></dd><dt>6. </dt><dd><div id="chediak-higashi.TF.3.6"><p class="no_margin">The conditioning regimen is at the discretion of the treatment center; however, reduced-intensity conditioning regimens have demonstrated improved survival over traditional myeloablative protocols.</p></div></dd><dt>7. </dt><dd><div id="chediak-higashi.TF.3.7"><p class="no_margin">Although not specific for CHS, in a cohort of 40 individuals with genetic forms of HLH including CHS, the three-year post-HSCT survival was 92% following reduced-intensity conditioning regimens [<a class="bk_pop" href="#chediak-higashi.REF.marsh.2010.5824">Marsh et al 2010</a>].</p></div></dd><dt>8. </dt><dd><div id="chediak-higashi.TF.3.8"><p class="no_margin">The overall five-year survival rate in 35 children with CHS who underwent HSCT was 62% [<a class="bk_pop" href="#chediak-higashi.REF.eapen.2007.411">Eapen et al 2007</a>].</p></div></dd><dt>9. </dt><dd><div id="chediak-higashi.TF.3.9"><p class="no_margin"><a class="bk_pop" href="#chediak-higashi.REF.bhambhani.2013.127">Bhambhani et al [2013]</a>, <a class="bk_pop" href="#chediak-higashi.REF.introne.2017.e57">Introne et al [2017]</a></p></div></dd></dl></div></div></div></div><div id="chediak-higashi.Prevention_of_Secondary"><h3>Prevention of Secondary Complications</h3><div id="chediak-higashi.T.prevention_of_secondar" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p>Prevention of Secondary Complications in Individuals with Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.prevention_of_secondar/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.prevention_of_secondar_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Manifestation/<br />Concern</th><th id="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Prevention</th><th id="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Considerations/Other</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Infection</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Inactivated vaccine administration according to typical schedule</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Live vaccines are not recommended.&#x000a0;<sup>1</sup></div></li><li class="half_rhythm"><div>Protection from infectious exposures as much as practical</div></li></ul>
</td></tr><tr><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Antibiotic &#x00026; antiviral agents should be used promptly &#x00026; aggressively for bacterial &#x00026; viral illnesses, respectively.</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consideration of prophylactic antibiotics in those w/recurrent infections&#x000a0;<sup>2,&#x000a0;3</sup></td></tr><tr><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bleeding<br />tendency</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Intravenous DDAVP (0.2-0.4 &#x000b5;g/kg/dose over 15-30 mins) 30 mins prior to invasive procedures</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">For serious trauma or extensive bleeding, platelet transfusion may be necessary.</td></tr><tr><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin cancer</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sunscreen (see <a href="#chediak-higashi.Treatment_of_Manifestati">Treatment of Manifestations</a>)</td><td headers="hd_h_chediak-higashi.T.prevention_of_secondar_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.4.1"><p class="no_margin"><a class="bk_pop" href="#chediak-higashi.REF.principi.2014.3725">Principi &#x00026; Esposito [2014]</a>, <a class="bk_pop" href="#chediak-higashi.REF.sobh.2016.1066">Sobh &#x00026; Bonilla [2016]</a></p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.4.2"><p class="no_margin"><a class="bk_pop" href="#chediak-higashi.REF.mccusker.2011.s11">McCusker &#x00026; Warrington [2011]</a></p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.4.3"><p class="no_margin">For individuals with compromised immune systems and neutropenia who will be undergoing invasive dental procedures or procedures that cause significant bleeding, prophylaxis should be considered [AAPD reference manual].</p></div></dd></dl></div></div></div></div><div id="chediak-higashi.Surveillance"><h3>Surveillance</h3><p>No consensus guidelines for surveillance of classic CHS exist. Generally, evaluation for bone marrow transplantation is initiated after the diagnosis is confirmed (see <a href="#chediak-higashi.Treatment_of_Manifestati">Treatment of Manifestations</a>).</p><div id="chediak-higashi.T.recommended_surveillan" class="table"><h3><span class="label">Table 5. </span></h3><div class="caption"><p>Recommended Surveillance for Individuals with Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.recommended_surveillan/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.recommended_surveillan_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hematologic</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Monitoring of chimerism&#x000a0;<sup>1,&#x000a0;2</sup></td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Routine</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Neurologic examination</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ocular</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Ophthalmologic examination</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Skin</td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dermatologic examination&#x000a0;<sup>3</sup></td><td headers="hd_h_chediak-higashi.T.recommended_surveillan_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.5.1"><p class="no_margin">Especially in those who undergo HSCT with reduced-intensity conditioning as the incidence of mixed chimerism in the bone marrow is higher than in those who undergo traditional conditioning.</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.5.2"><p class="no_margin">Recent studies suggest 20%-30% donor chimerism is likely enough to protect against reactivation [<a class="bk_pop" href="#chediak-higashi.REF.hartz.2016.3281">Hartz et al 2016</a>].</p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.5.3"><p class="no_margin">For routine monitoring in the setting of hypopigmentation</p></div></dd></dl></div></div></div><div id="chediak-higashi.T.additional_recommended" class="table"><h3><span class="label">Table 6. </span></h3><div class="caption"><p>Additional Recommended Surveillance for Individuals with Atypical or Adult-Onset Chediak-Higashi Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.additional_recommended/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.additional_recommended_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.additional_recommended_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">System/Concern</th><th id="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Evaluation</th><th id="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frequency&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_1" rowspan="7" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Hematologic</td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abdominal ultrasound&#x000a0;<sup>2</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Complete blood count&#x000a0;<sup>3</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Ferritin concentration&#x000a0;<sup>4</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Soluble interleukin-2 receptor level&#x000a0;<sup>4</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Serum triglyceride concentration&#x000a0;<sup>5</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Fibrinogen level&#x000a0;<sup>6</sup></td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">At least annually</td></tr><tr><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Consideration of bone marrow biopsy</td><td headers="hd_h_chediak-higashi.T.additional_recommended_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">If history, physical examination, or laboratory findings suggest the accelerated phase</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="chediak-higashi.TF.6.1"><p class="no_margin">The frequency listed can be modified based on changes in clinical status.</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.6.2"><p class="no_margin">To monitor for hepatosplenomegaly</p></div></dd><dt>3. </dt><dd><div id="chediak-higashi.TF.6.3"><p class="no_margin">To evaluate for cytopenias</p></div></dd><dt>4. </dt><dd><div id="chediak-higashi.TF.6.4"><p class="no_margin">Elevated serum ferritin and soluble interleukin-2 receptor level are associated with the accelerated phase.</p></div></dd><dt>5. </dt><dd><div id="chediak-higashi.TF.6.5"><p class="no_margin">Elevated levels may be a sign of liver dysfunction.</p></div></dd><dt>6. </dt><dd><div id="chediak-higashi.TF.6.6"><p class="no_margin">Low levels may be a sign of liver dysfunction.</p></div></dd></dl></div></div></div></div><div id="chediak-higashi.AgentsCircumstances_to_A"><h3>Agents/Circumstances to Avoid</h3><p>All nonsteroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) are to be avoided as they can exacerbate the bleeding tendency. Live vaccines should also be avoided.</p></div><div id="chediak-higashi.Evaluation_of_Relatives"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to evaluate the older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> as early as possible. Early diagnosis may provide the opportunity to perform HSCT prior to the development of the accelerated phase.</p><ul><li class="half_rhythm"><div>If the family-specific pathogenic variants are known, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can be used to clarify the genetic status of at-risk sibs.</div></li><li class="half_rhythm"><div>If the pathogenic variants in the family are not known, examination of peripheral blood for the presence of giant inclusions within white blood cells can be used to clarify the disease status of at-risk sibs.</div></li></ul><p>See <a href="#chediak-higashi.Related_Genetic_Counseli">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="chediak-higashi.Pregnancy_Management"><h3>Pregnancy Management</h3><p>In the limited cases of pregnancy in females with CHS reported in the literature [<a class="bk_pop" href="#chediak-higashi.REF.price.1992.804">Price et al 1992</a>, <a class="bk_pop" href="#chediak-higashi.REF.weisfeldadams.2013.46">Weisfeld-Adams et al 2013</a>], presence of the disease had no impact on the pregnancy, labor, or delivery. The infants were normal. The pregnancy also did not appear to affect the course of disease in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> mothers.</p></div><div id="chediak-higashi.Therapies_Under_Investig"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="chediak-higashi.Genetic_Counseling"><h2 id="_chediak-higashi_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="chediak-higashi.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Chediak-Higashi syndrome (CHS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="chediak-higashi.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are usually obligate heterozygotes (i.e., carriers of one <i>LYST</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Two individuals with CHS caused by <a class="def" href="/books/n/gene/glossary/def-item/uniparental-disomy/">uniparental disomy</a> of <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> 1 have been reported [<a class="bk_pop" href="#chediak-higashi.REF.dufourcqlagelouse.1999.633">Dufourcq-Lagelouse et al 1999</a>, <a class="bk_pop" href="#chediak-higashi.REF.manoli.2010.1474">Manoli et al 2010</a>]. Therefore, <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status of parents needs to be confirmed with <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, if the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are both heterozygotes, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with CHS are obligate heterozygotes (carriers) for a <i>LYST</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>.</p></div><div id="chediak-higashi.Carrier_Heterozygote_Det"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>LYST</i> pathogenic variants in the family.</p></div><div id="chediak-higashi.Related_Genetic_Counseli"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#chediak-higashi.Evaluation_of_Relatives">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="chediak-higashi.Prenatal_Testing_and_Pre"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>LYST</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="chediak-higashi.Resources"><h2 id="_chediak-higashi_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/ency/article/001312.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Chediak-Higashi syndrome</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=chediakhigashisyndrome" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Chediak-Higashi syndrome</a></div></li><li class="half_rhythm"><div><b>Hermansky-Pudlak Syndrome Network, Inc.</b></div><div>One South Road</div><div>Oyster Bay NY 11771-1905</div><div><b>Phone:</b> 800-789-9HPS</div><div><b>Fax:</b> 516-624-0640</div><div><b>Email:</b> info@hpsnetwork.org</div><div><a href="http://www.hpsnetwork.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hpsnetwork.org</a></div></li><li class="half_rhythm"><div><b>International Patient Organisation for Primary Immunodeficiencies (IPOPI)</b></div><div>Firside</div><div>Main Road</div><div>Downderry Cornwall PL11 3LE</div><div>United Kingdom</div><div><b>Phone:</b> +44 01503 250 668</div><div><b>Fax:</b> +44 01503 250 668</div><div><b>Email:</b> info@ipopi.org</div><div><a href="http://ipopi.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ipopi.org</a></div></li><li class="half_rhythm"><div><b>National Organization of Albinism and Hypopigmentation (NOAH)</b></div><div>PO Box 959</div><div>East Hampstead NH 03826-0959</div><div><b>Phone:</b> 800-473-2310 (toll-free); 603-887-2310</div><div><b>Fax:</b> 800-648-2310 (toll-free)</div><div><b>Email:</b> info@albinism.org</div><div><a href="http://www.albinism.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.albinism.org</a></div></li><li class="half_rhythm"><div><b>European Society for Immunodeficiencies (ESID) Registry</b></div><div>Dr. Gerhard Kindle</div><div>University Medical Center Freiburg Centre of Chronic Immunodeficiency</div><div>Engesserstr. 4</div><div>79106 Freiburg </div><div>Germany</div><div><b>Phone:</b> 49-761-270-34450</div><div><b>Email:</b> esid-registry@uniklinik-freiburg.de</div><div><a href="http://esid.org/Working-Parties/Registry" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ESID Registry</a></div></li></ul></div><div id="chediak-higashi.Molecular_Genetics"><h2 id="_chediak-higashi_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="chediak-higashi.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Chediak-Higashi Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_chediak-higashi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/1130" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>LYST</i></a></td><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=1130" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">1q42<wbr style="display:inline-block"></wbr>​.3</a></td><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q99698" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lysosomal-trafficking regulator</a></td><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.retina-international.org/files/sci-news/chsmut.htm" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Retina International Mutations of the Chediak Higashi Syndrome (LYST)</a><br /><a href="http://databases.lovd.nl/shared/genes/LYST" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LYST database</a><br /><a href="http://structure.bmc.lu.se/idbase/LYSTbase/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LYSTbase: Mutation registry for Chediak-Higashi syndrome (previously known as CHS1base)</a><br /><a href="http://www.ifpcs.org/albinism/chs1mut.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Albinism Database Mutations of the Chediak-Higashi Syndrome gene - LYST</a></td><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=LYST" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LYST</a></td><td headers="hd_b_chediak-higashi.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=LYST[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">LYST</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="chediak-higashi.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="chediak-higashi.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Chediak-Higashi Syndrome (<a href="/omim/214500,606897" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/214500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">214500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CHEDIAK-HIGASHI SYNDROME; CHS</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/606897" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">606897</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">LYSOSOMAL TRAFFICKING REGULATOR; LYST</td></tr></tbody></table></div></div><p><b>Gene structure.</b>
<i>LYST</i> is a large <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> with 53 exons. The 13.5-kb gene transcript produces a protein of 3,801 amino acids with a molecular weight of 430 kd. For a detailed summary of gene and protein information, see <a href="/books/NBK5188/#chediak-higashi.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> See <a class="figpopup" href="/books/NBK5188/table/chediak-higashi.T.selected_lyst_pathogen/?report=objectonly" target="object" rid-figpopup="figchediakhigashiTselectedlystpathogen" rid-ob="figobchediakhigashiTselectedlystpathogen">Table 7</a>. To date, 75 pathogenic variants have been identified throughout the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>. These include <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants, and small deletions and insertions in the <a class="def" href="/books/n/gene/glossary/def-item/coding-region/">coding region</a>.</p><div id="chediak-higashi.T.selected_lyst_pathogen" class="table"><h3><span class="label">Table 7. </span></h3><div class="caption"><p>Selected <i>LYST</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK5188/table/chediak-higashi.T.selected_lyst_pathogen/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__chediak-higashi.T.selected_lyst_pathogen_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.118dupG</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala40GlyfsTer24<br />(Ala40fsTer63)</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_3" rowspan="41" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/entrez/viewer.fcgi?val=NM_000081.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000081<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/entrez/viewer.fcgi?val=NP_000072.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000072<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.148C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg50Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.772T&#x0003e;C<br />(961T&#x0003e;C)&#x000a0;<sup>2</sup></td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Cys258Arg</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.925C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg309Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1467delG</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu489AspfsTer78<br />(Glu489fsTer566)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1540C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg514Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.1902dupA<br />(1897_1898insA)</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala635SerfsTer4<br />(Lys633fsTer638)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2413delG</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu805AsnfsTer2<br />(Glu805fsTer806)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2454delA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala819Hisfs5<br />(Lys818fsTer823)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2623delT<br />(2620delT)</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr875MetfsTer24<br />(Phe874fsTer898)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3073_3074delAA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn1025GlnfsTer6<br />(Asn1025fsTer1030)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3085C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1029Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3310C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1104Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3434dupA<br />(3434_3435insA)</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.His1145GlnfsTer9<br />(His1145fsTer1153)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3622C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1208Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.3944dupC<br />(3944_3945insC)</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr1315fsTer1331</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4052C&#x0003e;G</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser1351Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4361C&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala1454Asp</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4274delT</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu1425TyrfsTer2<br />(Leu1425fsTer1426)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.4688G&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1563His</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5061T&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr1687Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5317delA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1773AspfsTer13<br />(Arg1773fsTer1785)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5506C&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg1836Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5541_5542delAA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gln1847fsTer1850</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.5996T&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Val1999Asp</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.6078C&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr2026Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7060_7066delCTATTAG</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Leu2354MetfsTer16<br />(Leu2354fsTer2369)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7555delT</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr2519IlefsTer10<br />(Tyr2519fsTer2528)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.7982C&#x0003e;G</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ser2661Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.8281A&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg2761Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.8428G&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu2810Lys</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.8583G&#x0003e;A</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Trp2861Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9107_9162del56</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly3036GlufsTer16<br />(Gly3036fsTer3051)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9228_9229insTTCTTTCAGT</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Lys3077PhefsTer4<br />(Lys3077fsTer3080)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9590delA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Tyr3197LeufsTer62<br />(Tyr3197fsTer3258)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9827_9832delATACAA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn3276_Thr3277del</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.9893delT</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Phe3298Serfs7<br />(Phe3298fsTer3304)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10127A&#x0003e;G</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asn3376Ser</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.10395delA</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly3466AlafsTer2<br />(Lys3465fsTer3467)</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.11102G&#x0003e;T</td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Glu3668Ter</td></tr><tr><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.11173G&#x0003e;A<br />(11362G&#x0003e;A)&#x000a0;<sup>2</sup></td><td headers="hd_h_chediak-higashi.T.selected_lyst_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Gly3725Arg</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="chediak-higashi.TF.7.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="chediak-higashi.TF.7.2"><p class="no_margin"><a class="bk_pop" href="#chediak-higashi.REF.s_nchezguiu.2014.49">S&#x000e1;nchez-Guiu et al [2014]</a></p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b>
<i>LYST</i> encodes a 430-kd cytoplasmic protein with unknown biologic function called LYST (lysosomal-trafficking regulator) or CHS1. LYST is a member of the BEACH (beige and Chediak-Higashi) family of proteins, which are defined by the presence of a BEACH motif. The LYST N terminus has several ARM/HEAT repeats known to play a role in membrane interaction [<a class="bk_pop" href="#chediak-higashi.REF.kaplan.2008.22">Kaplan et al 2008</a>], whereas the C-terminal BEACH motif consists of a WIDL-enriched sequence followed by several WD-40 domains known to serve as a platform for protein-protein interaction [<a class="bk_pop" href="#chediak-higashi.REF.jogl.2002.4785">Jogl et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.de_lozanne.2003.6">De Lozanne 2003</a>, <a class="bk_pop" href="#chediak-higashi.REF.kaplan.2008.22">Kaplan et al 2008</a>].</p><p>The precise biologic role of LYST remains unknown. It has been hypothesized that LYST has a role in the regulation of membrane fusion events and lysosomal size [<a class="bk_pop" href="#chediak-higashi.REF.tanabe.2000.749">Tanabe et al 2000</a>, <a class="bk_pop" href="#chediak-higashi.REF.tchernev.2002.56">Tchernev et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.m_hlig.2007.2703">M&#x000f6;hlig et al 2007</a>, <a class="bk_pop" href="#chediak-higashi.REF.morimoto.2007.973">Morimoto et al 2007</a>]. More recently, it was proposed that LYST acts in membrane fusion and fission events as a scaffold protein [<a class="bk_pop" href="#chediak-higashi.REF.cullinane.2013.749">Cullinane et al 2013</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> CHS occurs through a <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> mechanism.</p><p>Many cell types in individuals with CHS manifest enlarged lysosomes or lysosome-related organelles; this is the main cellular characteristic of CHS [<a class="bk_pop" href="#chediak-higashi.REF.introne.1999.283">Introne et al 1999</a>, <a class="bk_pop" href="#chediak-higashi.REF.ward.2002.469">Ward et al 2002</a>, <a class="bk_pop" href="#chediak-higashi.REF.clark.2003.516">Clark &#x00026; Griffiths 2003</a>, <a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>]. In fibroblasts, enlarged lysosomes show a perinuclear distribution, and fusion with the plasma membrane in the wound healing process is inhibited [<a class="bk_pop" href="#chediak-higashi.REF.huynh.2004.16795">Huynh et al 2004</a>].</p><p>In epidermal melanocytes of individuals with CHS, oversized melanosomes accumulate in the perinuclear area and are not transferred to surrounding keratinocytes, which could explain the skin hypomelanosis observed in CHS [<a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>].</p><p>Enlarged mature lytic granules in CHS cytotoxic T-lymphocytes (CTLs) are unable to mediate targeted cell killing [<a class="bk_pop" href="#chediak-higashi.REF.stinchcombe.2000.435">Stinchcombe et al 2000</a>], and peptide loading onto MHC class II molecules and antigen presentation are delayed [<a class="bk_pop" href="#chediak-higashi.REF.faigle.1998.1121">Faigle et al 1998</a>]. A <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation has been noted within natural killer cells. Pathogenic variants in the ARM/HEAT <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> lead to a reduced number, but markedly enlarged, lytic granules that are capable of migrating to the immunologic synapse but unable to fuse with the plasma membrane. In contrast, pathogenic variants in the BEACH domain lead to normal or slightly enlarged granules that have impaired polarization to the immunologic synapse. In both cases, exocytosis of the lytic granules is impaired with significantly reduced cytotoxicity [<a class="bk_pop" href="#chediak-higashi.REF.gilkrzewska.2016.1165">Gil-Krzewska et al 2016</a>].</p><p>Most CHS platelets show absent dense bodies; a few platelets harbor enlarged and irregularly shaped dense bodies (<a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">Figure 1a</a>, <a class="figpopup" href="/books/NBK5188/figure/chediak-higashi.F1/?report=objectonly" target="object" rid-figpopup="figchediakhigashiF1" rid-ob="figobchediakhigashiF1">1b</a>) [<a class="bk_pop" href="#chediak-higashi.REF.white.2003.74">White 2003</a>, <a class="bk_pop" href="#chediak-higashi.REF.zarzour.2005.125">Zarzour et al 2005</a>, <a class="bk_pop" href="#chediak-higashi.REF.westbroek.2007.2674">Westbroek et al 2007</a>].</p><p>Interestingly, the neurologic findings of adult-onset Chediak-Higashi syndrome (CHS) resemble those of the ENU-induced <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> <i>Lyst<sup>Ing3618</sup></i> mouse, which manifests age-dependent neurologic impairment and Purkinje cell degeneration [<a class="bk_pop" href="#chediak-higashi.REF.rudelius.2006.267">Rudelius et al 2006</a>].</p></div><div id="chediak-higashi.References"><h2 id="_chediak-higashi_References_">References</h2><div id="chediak-higashi.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.bailleulforestier.2008.1263">Bailleul-Forestier I, Monod-Broca J, Benkerrou M, Mora F, Picard B. Generalized periodontitis associated with Chediak-Higashi syndrome. <span><span class="ref-journal">J Periodontol. </span>2008;<span class="ref-vol">79</span>:1263–70.</span> [<a href="/pubmed/18597610" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18597610</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.bergsten.2017.2728">Bergsten E, Horne A, Aric&#x000f3; M, Astigarraga I, Egeler RM, Filipovich AH, Ishii E, Janka G, Ladisch S, Lehmberg K, McClain KL, Minkov M, Montgomery S, Nanduri V, Rosso D, Henter JI. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. <span><span class="ref-journal">Blood. </span>2017;<span class="ref-vol">130</span>:2728–38.</span> [<a href="/pmc/articles/PMC5785801/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5785801</span></a>] [<a href="/pubmed/28935695" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28935695</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.bhambhani.2013.127">Bhambhani V, Introne WJ, Lungu C, Cullinane A, Toro C. Chediak-Higashi syndrome presenting as young-onset levodopa-responsive parkinsonism. <span><span class="ref-journal">Mov Disord. </span>2013;<span class="ref-vol">28</span>:127–9.</span> [<a href="/pmc/articles/PMC3581862/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3581862</span></a>] [<a href="/pubmed/23436631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23436631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.blume.1972.247">Blume RS, Wolff SM. The Chediak-Higashi syndrome: studies in four patients and a review of the literature. <span><span class="ref-journal">Medicine (Baltimore). </span>1972;<span class="ref-vol">51</span>:247–80.</span> [<a href="/pubmed/5064229" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5064229</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.bohn.2007.38">Bohn G, Allroth A, Brandes G, Thiel J, Glocker E, Sch&#x000e4;ffer AA, Rathinam C, Taub N, Teis D, Zeidler C, Dewey RA, Geffers R, Buer J, Huber LA, Welte K, Grimbacher B, Klein C. A novel human primary immunodeficiency syndrome caused by deficiency of the endosomal adaptor protein p14. <span><span class="ref-journal">Nature Medicine. </span>2007;<span class="ref-vol">13</span>:38–45.</span> [<a href="/pubmed/17195838" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17195838</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.chiyonobu.2002.61">Chiyonobu T, Yoshihara T, Fukushima Y, Yamamoto Y, Tsunamoto K, Nishimura Y, Ishida H, Toda T, Kasubuchi Y. Sister and brother with Vici syndrome: agenesis of the corpus callosum, albinism, and recurrent infections. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">109</span>:61–6.</span> [<a href="/pubmed/11932994" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11932994</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.clark.2003.516">Clark R, Griffiths GM. Lytic granules, secretory lysosomes and disease. <span><span class="ref-journal">Curr Opin Immunol. </span>2003;<span class="ref-vol">15</span>:516–21.</span> [<a href="/pubmed/14499259" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14499259</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.cullinane.2013.749">Cullinane AR, Schaffer AA, Huizing M. The BEACH is hot: a LYST of emerging roles for BEACH-domain containing proteins in human disease. <span><span class="ref-journal">Traffic. </span>2013;<span class="ref-vol">14</span>:749–66.</span> [<a href="/pmc/articles/PMC3761935/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3761935</span></a>] [<a href="/pubmed/23521701" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23521701</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.de_lozanne.2003.6">De Lozanne A. The role of BEACH proteins in Dictyostelium. <span><span class="ref-journal">Traffic. </span>2003;<span class="ref-vol">4</span>:6–12.</span> [<a href="/pubmed/12535270" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12535270</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.del_campo.1999.479">del Campo M, Hall BD, Aeby A, Nassogne M-C, Verloes A, Roche C, Gonzalez C, Sanchez H, Garcia-Alix A, Cabanas F, Escudero RM, Hernandez R, Quero J. Albinism and agenesis of the corpus callosum with profound developmental delay: Vici syndrome, evidence for autosomal recessive inheritance. <span><span class="ref-journal">Am J Med Genet. </span>1999;<span class="ref-vol">85</span>:479–85.</span> [<a href="/pubmed/10405446" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10405446</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.dionisi_vici.1988.1">Dionisi Vici C, Sabetta G, Gambarara M, Vigevano F, Bertini E, Boldrini R, Parisi SG, Quinti I, Aiuti F, Fiorilli M. Agenesis of the corpus callosum, combined immunodeficiency, bilateral cataract, and hypopigmentation in two brothers. <span><span class="ref-journal">Am J Med Genet. </span>1988;<span class="ref-vol">29</span>:1–8.</span> [<a href="/pubmed/3344762" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3344762</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.dufourcqlagelouse.1999.633">Dufourcq-Lagelouse R, Lambert N, Duval M, Viot G, Vilmer E, Fischer A, Prieur M, de Saint Basile G. Chediak-Higashi syndrome associated with maternal uniparental isodisomy of chromosome 1. <span><span class="ref-journal">Eur J Hum Genet. </span>1999;<span class="ref-vol">7</span>:633–7.</span> [<a href="/pubmed/10482950" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10482950</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.eapen.2007.411">Eapen M, DeLaat CA, Baker KS, Cairo MS, Cowan MJ, Kurtzberg J, Steward CG, Veys PA, Filipovich AH. Hematopoietic cell transplantation for Chediak-Higashi syndrome. <span><span class="ref-journal">Bone Marrow Transplantation. </span>2007;<span class="ref-vol">39</span>:411–5.</span> [<a href="/pubmed/17293882" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17293882</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.faigle.1998.1121">Faigle W, Raposo G, Tenza D, Pinet V, Vogt AB, Kropshofer H, Fischer A, de Saint-Basile G, Amigorena S. Deficient peptide loading and MHC Class II endosomal sorting in a human genetic immunodeficiency disease: the Chediak-Higashi syndrome. <span><span class="ref-journal">J Cell Biol. </span>1998;<span class="ref-vol">141</span>:1121–34.</span> [<a href="/pmc/articles/PMC2137185/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2137185</span></a>] [<a href="/pubmed/9606205" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9606205</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.filipovich.2006.410">Filipovich AH. Hemophagocytic lymphohistiocytosis and related disorders. <span><span class="ref-journal">Curr Opin Allergy Clin Immunol. </span>2006;<span class="ref-vol">6</span>:410–5.</span> [<a href="/pubmed/17088644" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17088644</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.filipovich.2015.895">Filipovich AH, Chandrakasan S. Pathogenesis of hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Hematol Oncol Clin North Am. </span>2015;<span class="ref-vol">29</span>:895–902.</span> [<a href="/pubmed/26461149" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26461149</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.gilkrzewska.2016.1165">Gil-Krzewska A, Wood SM, Murakami Y, Nguyen V, Chiang SCC, Cullinane AR, Peruzzi G, Gahl WA, Coligan JE, Introne WJ, Bryceson YT, Krzewski K. Chediak-Higashi syndrome: lysosomal trafficking regulator domains regulate exocytosis of lytic granules but not cytokine secretion by natural killer cells. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2016;<span class="ref-vol">137</span>:1165–77.</span> [<a href="/pmc/articles/PMC4826811/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4826811</span></a>] [<a href="/pubmed/26478006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26478006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.hart.2007.95">Hart TC, Atkinson JC. Mendelian forms of periodontitis. <span><span class="ref-journal">Periodontol 2000. </span>2007;<span class="ref-vol">45</span>:95–112.</span> [<a href="/pubmed/17850451" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17850451</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.hartz.2016.3281">Hartz B, Marsh R, Rao K, Henter JI, Jordan M, Filipovich L, Bader P, Beier R, Burkhardt B, Meisel R, Schulz A, Winkler B, Albert MH, Greil J, Karasu G, Woessmann W, Corbacioglu S, Gruhn B, Holter W, K&#x000fc;hl JS, Lang P, Seidel MG, Veys P, L&#x000f6;fstedt A, Ammann S, Ehl S, Janka G, M&#x000fc;ller I, Lehmberg K. The minimum required level of donor chimerism in hereditary hemophagocytic lymphohistiocytosis. <span><span class="ref-journal">Blood. </span>2016;<span class="ref-vol">127</span>:3281–90.</span> [<a href="/pmc/articles/PMC5291300/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5291300</span></a>] [<a href="/pubmed/27099148" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27099148</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.huynh.2004.16795">Huynh C, Roth D, Ward DM, Kaplan J, Andrews NW. Defective lysosomal exocytosis and plasma membrane repair in Chediak-Higashi/beige cells. <span><span class="ref-journal">Proc Natl Acad Sci USA. </span>2004;<span class="ref-vol">101</span>:16795–800.</span> [<a href="/pmc/articles/PMC534728/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC534728</span></a>] [<a href="/pubmed/15557559" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15557559</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.introne.1999.283">Introne W, Boissy RE, Gahl WA. Clinical, molecular, and cell biological aspects of Chediak-Higashi syndrome. <span><span class="ref-journal">Mol Genet Metab. </span>1999;<span class="ref-vol">68</span>:283–303.</span> [<a href="/pubmed/10527680" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10527680</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.introne.2017.e57">Introne WJ, Westbroek W, Groden CA, Bhambhani V, Golas GA, Baker EH, Lehky TJ, Snow J, Ziegler SG, Malicdan MC, Adams DR, Horward HM, Hess RA, Huizing M, Gahl WA, Toro C. Neurologic involvement in patients with atypical Chediak-Higashi disease. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">88</span>:e57–e65.</span> [<a href="/pmc/articles/PMC5584077/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5584077</span></a>] [<a href="/pubmed/28193763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28193763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.jessen.2013.2943">Jessen B, Bode SF, Ammann S, Chakravorty S, Davies G, Diestelhorst J, Frei-Jones M, Gahl WA, Gochuico BR, Griese M, Griffiths G, Janka G, Klein C, K&#x000f6;gl T, Kurnik K, Lehmberg K, Maul-Pavicic A, Mumford AD, Pace D, Parvaneh N, Rezaei N, de Saint Basile G, Schmitt-Graeff A, Schwarz K, Karasu GT, Zieger B, Zur Stadt U, Aichele P, Ehl S. The risk of hemophagocytic lymphohistiocytosis in Hermansky-Pudlak syndrome type 2. <span><span class="ref-journal">Blood. </span>2013;<span class="ref-vol">121</span>:2943–51.</span> [<a href="/pmc/articles/PMC3624940/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3624940</span></a>] [<a href="/pubmed/23403622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23403622</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.jessen.2011.4620">Jessen B, Maul-Pavicic A, Ufheil H, Vraetz T, Enders A, Lehmberg K, Langler A, Gross-Wieltsch U, Bay A, Kaya Z, Bryceson YT, Koscielniak E, Badawy S, Davies G, Hufnagel M, Schmitt-Graeff A, Aichele P, Zur Stadt U, Schwarz K, Ehl S. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. <span><span class="ref-journal">Blood. </span>2011;<span class="ref-vol">118</span>:4620–9.</span> [<a href="/pubmed/21878672" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21878672</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.jogl.2002.4785">Jogl G, Shen Y, Gebauer D, Li J, Wiegmann K, Kashkar H, Kr&#x000f6;nke M, Tong L. Crystal structure of the BEACH domain reveals an unusual fold and extensive association with a noval PH domain. <span><span class="ref-journal">EMBO J. </span>2002;<span class="ref-vol">21</span>:4785–95.</span> [<a href="/pmc/articles/PMC126298/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC126298</span></a>] [<a href="/pubmed/12234919" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12234919</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.kaplan.2008.22">Kaplan J, De Domenico I, Ward DM. Chediak Higashi Syndrome. <span><span class="ref-journal">Curr Opin Hematol. </span>2008;<span class="ref-vol">15</span>:22–9.</span> [<a href="/pubmed/18043242" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18043242</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.karim.2002.16">Karim MA, Suzuki K, Fukai K, Oh J, Nagle DL, Moore KJ, Barbosa E, Falik-Borenstein T, Filipovich A, Ishida Y, Kivrikko S, Klein C, Kreuz F, Levin A, Miyajima H, Regueiro J, Russo C, Uyama E, Vierimaa O, Spritz RA. Apparent genotype-phenotype correlation in childhood, adolescent, and adult Chediak Higashi syndrome. <span><span class="ref-journal">Am J Med Genet. </span>2002;<span class="ref-vol">108</span>:16–22.</span> [<a href="/pubmed/11857544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11857544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.khocht.2010.49">Khocht A, Viera-Negron YE, Ameri A, Abdelsayed R. Periodontitis associated with Chediak-Higashi syndrome in a young African American male. <span><span class="ref-journal">J Int Acad Periodontol. </span>2010;<span class="ref-vol">12</span>:49–55.</span> [<a href="/pubmed/20465032" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20465032</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.lehky.2017.359">Lehky TJ, Groden C, Lear B, Toro C, Introne WJ. Peripheral nervous system manifestations of Chediak-Higashi disease. <span><span class="ref-journal">Muscle Nerve. </span>2017;<span class="ref-vol">55</span>:359–65.</span> [<a href="/pmc/articles/PMC5243934/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5243934</span></a>] [<a href="/pubmed/27429304" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27429304</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.manoli.2010.1474">Manoli I, Golas G, Westbroek W, Vilboux T, Markello TC, Introne W, Maynard D, Pederson B, Tsilou E, Jordan MB, Hart PS, White JG, Gahl WA, Huizing M. Chediak-Higashi syndrome with early developmental delay resulting from paternal heterodisomy of chromosome 1. <span><span class="ref-journal">Am J Med Genet A. </span>2010;<span class="ref-vol">152A</span>:1474–83.</span> [<a href="/pmc/articles/PMC2947940/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2947940</span></a>] [<a href="/pubmed/20503323" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20503323</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.marsh.2010.5824">Marsh RA, Vaughn G, Kim MO, Li D, Jodele S, Joshi S, Mehta PA, Davies SM, Jordan MB, Bleesing JJ, Filipovich AH. Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic hymphohistiocytosis undergoing allogenic hematopoietic cell transplantation. <span><span class="ref-journal">Blood. </span>2010;<span class="ref-vol">116</span>:5824–31.</span> [<a href="/pubmed/20855862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20855862</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.mccusker.2011.s11">McCusker C, Warrington R. Primary immunodeficiency. <span><span class="ref-journal">Allergy Asthma Clin Immunol. </span>2011;<span class="ref-vol">7</span> Suppl 1:S11.</span> [<a href="/pmc/articles/PMC3245434/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3245434</span></a>] [<a href="/pubmed/22165913" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22165913</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.m_nasch_.2003.450">M&#x000e9;nasch&#x000e9; G, Ho CH, Sanal O, Feldmann J, Tezcan I, Ersoy F, Houdusse A, Fischer A, de Saint Basile G. Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). <span><span class="ref-journal">J Clin Invest. </span>2003;<span class="ref-vol">112</span>:450–6.</span> [<a href="/pmc/articles/PMC166299/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC166299</span></a>] [<a href="/pubmed/12897212" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12897212</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.m_nasch_.2000.173">M&#x000e9;nasch&#x000e9; G, Pastural E, Feldmann J, Certain S, Ersoy F, Dupuis S, Wulffraat N, Bianchi D, Fischer A, Le Deist F, de Saint Basile G. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. <span><span class="ref-journal">Nat Genet. </span>2000;<span class="ref-vol">25</span>:173–6.</span> [<a href="/pubmed/10835631" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10835631</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.miyata.2007.189">Miyata R, Hayashi M, Sato H, Sugawara Y, Yui T, Araki S, Hasegawa T, Doi S, Kohyama J. Sibling cases of Vici syndrome: sleep abnormalities and complications of renal tubular acidosis. <span><span class="ref-journal">Am J Med Genet A. </span>2007;<span class="ref-vol">143A</span>:189–94.</span> [<a href="/pubmed/17163544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17163544</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.m_hlig.2007.2703">M&#x000f6;hlig H, Mathieu S, Thon L, Frederiksen MC, Ward DM, Kaplan J, Sch&#x000fc;tze S, Kabelitz D, Adam D. The WD repeat protein FAN regulates lysosome size independent from abnormal downregulation/membrane recruitment of protein kinase C. <span><span class="ref-journal">Exp Cell Res. </span>2007;<span class="ref-vol">313</span>:2703–18.</span> [<a href="/pmc/articles/PMC2988431/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2988431</span></a>] [<a href="/pubmed/17512928" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17512928</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.morimoto.2007.973">Morimoto M, Tanabe F, Kasai H, Ito M. Effect of a thiol proteinase inhibitor, E-64-d, on susceptibility to infection with Staphylococcus aureus in Chediak-Higashi syndrome (beige) mice. <span><span class="ref-journal">Int Immunopharmacol. </span>2007;<span class="ref-vol">7</span>:973–80.</span> [<a href="/pubmed/17499200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17499200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.pastural.1997.289">Pastural E, Barrat FJ, Dufourcq-Lagelouse R, Certain S, Sanal O, Jabado N, Seger R, Griscelli C, Fischer A, de Saint Basile G. Griscelli disease maps to chromosome 15q21 and is associated with mutations in the myosin-Va gene. <span><span class="ref-journal">Nat Genet. </span>1997;<span class="ref-vol">16</span>:289–92.</span> [<a href="/pubmed/9207796" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9207796</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.price.1992.804">Price FV, Legro RS, Watt-Morse M, Kaplan SS. Chediak-Higashi syndrome in pregnancy. <span><span class="ref-journal">Obstet Gynecol. </span>1992;<span class="ref-vol">79</span>:804–6.</span> [<a href="/pubmed/1565370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1565370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.principi.2014.3725">Principi N, Esposito S. Vaccine use in primary immunodeficiency disorders. <span><span class="ref-journal">Vaccine. </span>2014;<span class="ref-vol">32</span>:3725–31.</span> [<a href="/pubmed/24837766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24837766</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.rudelius.2006.267">Rudelius M, Osanger A, Kohlmann S, Augustin M, Piontek G, Heinzmann U, Jennen G, Russ A, Matiasek K, Stumm G, Schlegel J. A missense mutation in the WD40 domain of murine Lyst is linked to severe progressive Purkinje cell degeneration. <span><span class="ref-journal">Acta Neuropathol. </span>2006;<span class="ref-vol">112</span>:267–76.</span> [<a href="/pubmed/16791600" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16791600</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.s_nchezguiu.2014.49">S&#x000e1;nchez-Guiu I, Ant&#x000f3;n AI, Garc&#x000ed;a-Barber&#x000e1; N, Navarro-Fern&#x000e1;ndez J, Mart&#x000ed;nez C, Fuster JL, Couselo JM, Ortu&#x000f1;o FJ, Vicente V, Rivera J, Lozano ML. Chediak-Higashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. <span><span class="ref-journal">Eur J Haematol. </span>2014;<span class="ref-vol">92</span>:49–58.</span> [<a href="/pubmed/24112114" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24112114</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.shimazaki.2014.1024">Shimazaki H, Honda J, Naoi T, Namekawa M, Nakano I, Yazaki M, Nakamura K, Yoshida K, Ikeda S, Ishiura H, Fukuda Y, Takahashi Y, Goto J, Tsuji S, Takiyama Y. Autosomal-recessive complicated spastic paraplegia with a novel lysosomal trafficking regulator gene mutation. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2014;<span class="ref-vol">85</span>:1024–8.</span> [<a href="/pubmed/24521565" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24521565</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.smith.2005.1294">Smith VV, Anderson G, Malone M, Sebire NJ. Light microscopic examination of scalp hair samples as an aid in the diagnosis of paediatric disorders: retrospective review of more than 300 cases from a single centre. <span><span class="ref-journal">J Clin Pathol. </span>2005;<span class="ref-vol">58</span>:1294–8.</span> [<a href="/pmc/articles/PMC1770794/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1770794</span></a>] [<a href="/pubmed/16311350" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16311350</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.sobh.2016.1066">Sobh A, Bonilla FA. Vaccination in primary immunodeficiency disorders. <span><span class="ref-journal">J Allergy Clin Immunol Pract. </span>2016;<span class="ref-vol">4</span>:1066–75.</span> [<a href="/pubmed/27836056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27836056</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.stinchcombe.2000.435">Stinchcombe JC, Page Lj, Griffiths GM. Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak Higashi syndrome patients. <span><span class="ref-journal">Traffic. </span>2000;<span class="ref-vol">1</span>:435–44.</span> [<a href="/pubmed/11208129" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11208129</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.tanabe.2000.749">Tanabe F, Cui SH, Ito M. Abnormal down-regulation of PKC is responsible for giant granule formation in fibroblasts from CHS (beige) mice--a thiol proteinase inhibitor, E-64-d, prevents giant granule formation in beige fibroblasts. <span><span class="ref-journal">J Leukoc Biol. </span>2000;<span class="ref-vol">67</span>:749–55.</span> [<a href="/pubmed/10811017" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10811017</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.tardieu.2005.40">Tardieu M, Lacroix C, Neven B, Bordigoni P, de Saint Basile G, Blanche S, Fischer A. Progressive neurologic dysfunctions 20 years after allogeneic bone marrow transplantation for Chediak-Higashi syndrome. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">106</span>:40–2.</span> [<a href="/pubmed/15790783" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15790783</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.tchernev.2002.56">Tchernev VT, Mansfield TA, Giot L, Kumar AM, Nandabalan K, Li Y, Mishra VS, Detter JC, Rothberg JM, Wallace MR, Southwick FS, Kingsmore SF. The Chediak-Higashi protein interacts with SNARE complex and signal transduction proteins. <span><span class="ref-journal">Mol Med. </span>2002;<span class="ref-vol">8</span>:56–64.</span> [<a href="/pmc/articles/PMC2039936/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2039936</span></a>] [<a href="/pubmed/11984006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11984006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.trottestam.2009.268">Trottestam H, Beutel K, Meeths M, Carlsen N, Heilmann C, Pasi&#x00107; S, Webb D, Hasle H, Henter JI. Treatment of the X-linked lymphoproliferative, Griscelli and Chediak-Higashi syndromes by HLH directed therapy. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2009;<span class="ref-vol">52</span>:268–72.</span> [<a href="/pubmed/18937330" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18937330</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.ward.2002.469">Ward DM, Shiflett SL, Kaplan J. Chediak Higashi Syndrome: a clinical and molecular view of a rare lysosomal storage disorder. <span><span class="ref-journal">Curr Mol Med. </span>2002;<span class="ref-vol">2</span>:469–77.</span> [<a href="/pubmed/12125812" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12125812</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.weisfeldadams.2013.46">Weisfeld-Adams JD, Mehta L, Rucker JC, Dembitzer FR, Szporn A, Lublin FD, Introne WJ, Bhambhani V, Chicka MC, Cho C. Atypical Chediak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2013;<span class="ref-vol">8</span>:46.</span> [<a href="/pmc/articles/PMC3610301/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3610301</span></a>] [<a href="/pubmed/23521865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23521865</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.westbroek.2007.2674">Westbroek W, Adams D, Huizing M, Koshoffer A, Dorward H, Tinloy B, Parkes J, Helip-Wooley A, Kleta R, Tsilou E, Duvernay P, Digre KB, Creel DJ, White JG, Boissy RE, Gahl WA. The severity of cellular defects in Chediak Higashi syndrome correlate with the molecular genotype and clinical phenotype. <span><span class="ref-journal">J Invest Dermatol. </span>2007;<span class="ref-vol">127</span>:2674–7.</span> [<a href="/pubmed/17554367" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17554367</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.white.2003.74">White JG. Electron-dense chains and clusters in platelets from patients with storage pool-deficiency disorders. <span><span class="ref-journal">J Thromb Haemost. </span>2003;<span class="ref-vol">1</span>:74–9.</span> [<a href="/pubmed/12871542" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12871542</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="chediak-higashi.REF.zarzour.2005.125">Zarzour W, Kleta R, Frangoul H, Suwannarat P, Jeong A, Kim SY, Wayne AS, Gunay-Aygun M, White J, Filipovich AH, Gahl WA. Two novel CHS1 (LYST) mutations: clinical correlations in an infant with Chediak-Higashi syndrome. <span><span class="ref-journal">Mol Genet Metab. </span>2005;<span class="ref-vol">85</span>:125–32.</span> [<a href="/pubmed/15896657" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15896657</span></a>]</div></li></ul></div></div><div id="chediak-higashi.Chapter_Notes"><h2 id="_chediak-higashi_Chapter_Notes_">Chapter Notes</h2><div id="chediak-higashi.Author_Notes"><h3>Author Notes</h3><p>Dr Toro is a movement-disorder neurologist who works with the National Institutes of Health Undiagnosed Diseases Program.</p><p>Dr Nicoli is a pharmacist and a scientist who studies lysosomal storage disorders, pathogenesis, and therapy.</p><p>Dr Malicdan is a neurologist and a scientist, whose main interest is to study rare diseases.</p><p>Dr Adams is a pediatrician, medical geneticist, and biochemical geneticist who performs clinical and basic research into rare diseases at the National Institutes of Health.</p><p>Dr Introne is a pediatrician and medical and biochemical geneticist who performs clinical research on rare diseases at the National Institutes of Health</p></div><div id="chediak-higashi.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank Dr William Gahl and Dr Alan Wayne for their commitment to the care of these individuals and dedication to furthering our understanding of the disease.</p></div><div id="chediak-higashi.Author_History"><h3>Author History</h3><p>David R Adams, MD, PhD (2009-present)<br />Gretchen A Golas, RN, MS, CRNP; National Human Genome Research Institute (2009-2018)<br />Wendy J Introne, MD (2009-present)<br />May Christine Malicdan, MD, PhD (2018-present)<br />Elena-Raluca Nicoli, PharmR, PhD (2018-present)<br />Camilo Toro, MD (2018-present)<br />Wendy Westbroek, PhD; National Human Genome Research Institute (2009-2018)</p></div><div id="chediak-higashi.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>5 July 2018 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>15 January 2015 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>16 February 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>27 July 2010 (cd) Revision: prenatal testing available clinically</div></li><li class="half_rhythm"><div>11 August 2009 (cd) Revision: <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> available clinically</div></li><li class="half_rhythm"><div>3 March 2009 (me) Review posted live</div></li><li class="half_rhythm"><div>2 October 2008 (wji) Original submission</div></li></ul><p>Note: Pursuant to 17 USC Section 105 of the United States Copyright Act, the <i>GeneReview</i> "Chediak-Higashi Syndrome" is in the public <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> in the United States of America.</p></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK5188</span><span class="label">PMID: <a href="/pubmed/20301751" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301751</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cmtx5/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/cherubism/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK5188&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK5188/?report=reader">PubReader</a></li><li><a href="/books/NBK5188/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK5188" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK5188" style="display:none" title="Cite this Page"><div class="bk_tt">Toro C, Nicoli ER, Malicdan MC, et al. Chediak-Higashi Syndrome. 2009 Mar 3 [Updated 2018 Jul 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK5188/pdf/Bookshelf_NBK5188.pdf">PDF version of this page</a> (770K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#chediak-higashi.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#chediak-higashi.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#chediak-higashi.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#chediak-higashi.Genetically_Related_Alle" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#chediak-higashi.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#chediak-higashi.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#chediak-higashi.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#chediak-higashi.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#chediak-higashi.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#chediak-higashi.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#chediak-higashi.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=1130[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">LYST</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK5188+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1469452" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1469452" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1469452" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1469452" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301464" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hermansky-Pudlak Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Huizing M, Malicdan MCV, Gochuico BR, Gahl WA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23804531" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Clinical characteristics and outcomes of chédiak-Higashi syndrome: a nationwide survey of Japan.</a><span class="source">[Pediatr Blood Cancer. 2013]</span><div class="brieflinkpop offscreen_noflow">Clinical characteristics and outcomes of chédiak-Higashi syndrome: a nationwide survey of Japan.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Nagai K, Ochi F, Terui K, Maeda M, Ohga S, Kanegane H, Kitoh T, Kogawa K, Suzuki N, Ohta S, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Blood Cancer. 2013 Oct; 60(10):1582-6. Epub 2013 Jun 27.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26225414" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lysosomal Acid Lipase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Lysosomal Acid Lipase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hoffman EP, Barr ML, Giovanni MA, Murray MF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/28145517" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Whole Genome Sequencing Identifies Novel Compound Heterozygous Lysosomal Trafficking Regulator Gene Mutations Associated with Autosomal Recessive Chediak-Higashi Syndrome.</a><span class="source">[Sci Rep. 2017]</span><div class="brieflinkpop offscreen_noflow">Whole Genome Sequencing Identifies Novel Compound Heterozygous Lysosomal Trafficking Regulator Gene Mutations Associated with Autosomal Recessive Chediak-Higashi Syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jin Y, Zhang L, Wang S, Chen F, Gu Y, Hong E, Yu Y, Ni X, Guo Y, Shi T, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Sci Rep. 2017 Feb 1; 7:41308. Epub 2017 Feb 1.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301575" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Fanconi Anemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mehta PA, Tolar J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301751" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301751" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc943b39a66ee2ba3e1b5d">Chediak-Higashi Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Chediak-Higashi Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:28:27-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8A5B77DFC93991000000000053002E&amp;ncbi_session=CE8A5B77DFC943A1_0083SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK5188%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK5188&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK5188/&amp;ncbi_pagename=Chediak-Higashi Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8A5B77DFC943A1_0083SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>